Rx Propellant becomes a part of the Actis portfolio
Rx Propellant has been acquired by Actis – a UK based global investment company for an
initial USD 200 million investment in May 2022. This investment places a focus on
sustainability in life science clusters in the cities of Hyderabad, Bengaluru and Mumbai.